AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06084819
Drug: Best-Available Therapy(BAT) Regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. FLAG regimen:Fludarabine(30mg/m2,days 1-5)+Cytarabine (1-2g/m2 applied 4h after fludarabine, days 1 to 5)+Granulocyte colony-stimulating factor(300ug/day,days 0 to 5)~2. CLAG regimen:Cladribine(5mg/2,days 1-5)+Cytarabine (1-2g/m2 applied 4h after fludarabine, days 1 to 5)+Granulocyte colony-stimulating factor(300ug/day,days 0 to 5)~3. MAE regimen:Mitox(10mg/m2,days 1 to 5)+VP-16(100mg/m2,days 1 to 5)+Cytarabine (100-150mg/m2,days 1 to 7)~4. DCAG regimen:Decitabine(20mg/m2,days 1 to 5)+Aclacinomycin(20mg/day on days 1,3,5)+Cytarabine (100mg q12h,days 1 to 5)+Granulocyte colony-stimulating factor(300 ug/day,day 0 until agranulocytosi recovery)~5. HAA regimen:HHT(2mg/m2,days 1 to 7)+Aclacinomycin(20mg/day,days 1 to 7) and Cytarabine (100-200 mg/m2, days 1 to 5);~6. HAD regimen:HHT(2mg/m2,days 1 to 7)+Daunorubicin(45mg/m2/day,days 1 to 3)+Cytarabine (100-200 mg/m2,days 1 to 5).
Trial: NCT05416476
Drug: Anisodine Hydrobromide
RxNorm normalized name: hydrobromic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anisodine Hydrobromide 1 mg oral tablet, twice times a day
Trial: NCT05416476
Drug: Anisodine Hydrobromide placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anisodine Hydrobromide Placebo 1 mg oral tablet, twice times a day
Trial: NCT06411925
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dry syrup, TID
Trial: NCT06665230
Drug: MK-6552
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT05531279
Drug: PEG-rhG-CSF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG-rhG-CSF group A(q7d):6mg d1,8,subcutaneously injected; PEG-rhG-CSF group B(q10d):6mg d1,11,subcutaneously injected; RhG-CSF group(short-acting ): 480ug d1-14(daily for 14days),subcutaneously injected.
Trial: NCT04184323
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: We will use the same vehicle for producing the active drug such as maltose without any hormones or active components
Trial: NCT05375474
Drug: Oral anticoagulation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin-K antagonists (warfarin)
Trial: NCT05375474
Drug: Single antiplatelet therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin
Trial: NCT06618391
Drug: recombinant human adenovirus type 5
RxNorm normalized name: adenovirus, type 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant Human Adenovirus Type 5: 1.0ml/time, intratumoral injection, at least 5 sites; Envolimab :Maintenance therapy 300 mg, Q3W for 4-6 cycles，, subcutaneous injection; administered on Day 1 of each cycle; Docetaxel: 60-75 mg/m2, D1, Q3W,for 4-6 cycles，intravenous drip.
Trial: NCT04939545
Drug: NaCl 0.9%
RxNorm normalized name: DEXTROSE 5%/NACL 0.9% INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intercostal continuous loco-regional placebo solution (NaCl 0,9%) administration over an elastomeric pump through a surgically placed intercostal catheter (ICC) for a maximum of 72h. As concomitant treatments a standardized anesthesia protocol including intravenous continuous application of propofol and remifentanil is used. Additionally, i.v. metamizol at a dose of 1 g will be administered at the end of surgery as a standard, if not contraindicated.~In a standardized postoperative pain protocol the use of basic oral medication is documented as part of the postoperative follow-up and consists of:~ibuprofen 3 x 400 mg p. o. for 3 days, metamizol 4 x 1 g p. o. for 3 days; if ibuprofen and/or metamizol contraindicated then paracetamol p. o. 3 x 1g for 3 days will be administered; morphine 10 mg p. o. 6 times daily will be given on a patient demand basis.
Trial: NCT06329687
Drug: Tyrvaya Nasal Pump
RxNorm normalized name: Tyrvaya Nasal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tyrvaya Nasal Pump with Silicone Lubricant
Trial: NCT06078709
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT06078709
Drug: Leucovorin Calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT05003102
Drug: Fentanyl - PICU Standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fentanyl infusion at 1 mcg/kg/hr up to a max drip rate of 5 mcg/kg/hr
Trial: NCT05306366
Drug: [11C]-Lu AF90103
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PET ligand administrated as a single intravenous bolus injection
Trial: NCT06277635
Drug: Silymarin
RxNorm normalized name: silymarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silymarin is randomly assigned to the participants for 12 weeks during study.
Trial: NCT06277635
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is randomly assigned to the participants for 12 weeks during study.
Trial: NCT04157114
Drug: MAP4343
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive daily oral doses of MAP4343 for 6 weeks in conjunction with 6 weeks of manual-guided counseling
Trial: NCT04157114
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects receive matched placebo for 6 weeks in conjunction with 6 weeks of manual-guided counseling
Trial: NCT04731155
Drug: standard medications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard medications was giving to subjects according guidelines
Trial: NCT04530058
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo twice a day, administered orally or via gastric tube.
Trial: NCT05088369
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered intravenously.
Trial: NCT06662526
Drug: Placebo pill plus treatment as usual
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive a placebo pill plus treatment as usual by their clinical providers
Trial: NCT05804045
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsule
Trial: NCT04729179
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is administered as tablets of 10 mg that are identical in appearance, taste, and smell to the Cannabidiol tablets.The participants will be on the 50 mg dosage of placebo for 24 weeks.
Trial: NCT05206955
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Looks exactly like the study drug, but it contains no active ingredient
Trial: NCT04660799
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide will be administered IV at a dose of 750 mg/m\^2
Trial: NCT04660799
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin will be administered IV at a dose of 50 mg/m\^2
Trial: NCT06684509
Drug: Atrovastain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: atorvaststin 40mg/daily , started before anthracyclin treatment and continued 12 months
Trial: NCT06666166
Drug: SHR-A1811 & Apartinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR-A1811 injection will be administered by intravenous infusion. And apatinib will be administered orally.
Trial: NCT04796623
Drug: TQB3616 capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQB3616 capsules 180 mg given orally, once daily in 28-day cycle.
Trial: NCT05622058
Drug: ALRN-6924
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALRN-6924 administered in every chemotherapy treatment cycle as an IV infusion over 1 hour on Days 0 (approximately 18 hours prior to chemotherapy administration), 1 (approximately 1 hour prior to chemotherapy administration), and 2 (approximately 24 hours after the second infusion of ALRN-6924).
Trial: NCT04865744
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet is taken after an overnight fast with up to120 ml of water.
Trial: NCT05052398
Drug: Placebo PSP NEURO SERUM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo PSP NEURO SERUM is the same topical product as PSP NEURO SERUM without the active ingredient. Each patient will apply 1 g of Placebo PSP NEURO SERUM in their hands, three times a day.
Trial: NCT04780152
Drug: Fluoxetine Tablets
RxNorm normalized name: Fluoxetine Tablets
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Every patient will receive 10 mg of fluoxetine daily the first 2 two weeks, followed by 20 mg daily.
Trial: NCT00001016
Drug: Leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04863339
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single preoperative dose of 100 mL of saline placebo given 0-30 minutes prior to surgery.
Trial: NCT06157099
Drug: Placebo Administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given orally (PO)
Trial: NCT05354102
Drug: BMC128
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A live bio-therapeutic product composed of 4 commensal bacterial strains, natural inhabitants of the human intestinal tract.
Trial: NCT06322095
Drug: MET inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Previous MET inhibitor
Trial: NCT06322095
Drug: BRAF Inhibito
RxNorm normalized name: B-Raf serine-threonine kinase (BRAF) inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Previous BRAF inhibitor
Trial: NCT06322095
Drug: MEK Inhibitor
RxNorm normalized name: Mitogen-activated protein kinase (MEK) inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Previous MEK Inhibitor
Trial: NCT05543109
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 mic/kg during induction of anesthesia
Trial: NCT06550011
Drug: ABI-110 Low Dose
RxNorm normalized name: PICEA ABIES WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose. lower than the safety factor of 10 as recommended by the FDA
Trial: NCT06550011
Drug: ABI-110 Medium Dose
RxNorm normalized name: PICEA ABIES WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium dose
Trial: NCT06550011
Drug: ABI-110 High Dose
RxNorm normalized name: PICEA ABIES WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High Dose
Trial: NCT05245916
Drug: IBI397
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IBI397 single-agent dose escalation： Subjects will receive IBI397 until disease progression, unacceptable toxicity, withdrawal of consent, occurrence of other conditions that require discontinuation of study treatment, or the treatment duration has reached 24 months, whichever occurs first
Trial: NCT04945421
Drug: IBI310
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (IBI310 3 mg/kg IV d1, Q3W combined with sintilimab 100 mg IV d1, Q3W) or( IBI310 1 mg/kg IV d1, Q3W combined with sintilimab 200 mg IV d1, Q3W) for up to 4 cycles, and then sintilimab 200 mg IV d1, Q3W until progressive disease, intolerable toxicity, start of a new antitumor treatment, withdrawal of informed consent, loss to follow-up, death or other situations requiring termination of treatment specified in the protocol, whichever occurs first.
Trial: NCT05545800
Drug: IDegLira
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomization was performed with the use of a computer-generated system provided by the sponsor. Eligible patients will be initiated on 16 units (16 units degludec/0.58 mg liraglutide) and titrated twice weekly. The maximum dose of IDegLira was 50 units (50 units degludec/1.8 mg liraglutide). All groups received counseling on lifestyle modification.
Trial: NCT05568121
Drug: L04RD1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet of L04RD1
Trial: NCT05568121
Drug: L04TD1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet of L04TD1
Trial: NCT06212648
Drug: SPC1001 Mid1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drugs for clinical trials are orally administered once a day after breakfast.~After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks.
Trial: NCT06212648
Drug: SPC4001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drugs for clinical trials are orally administered once a day after breakfast.~After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks.
Trial: NCT06212648
Drug: SPC4002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drugs for clinical trials are orally administered once a day after breakfast.~After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks.
Trial: NCT06212648
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drugs for clinical trials are orally administered once a day after breakfast.~After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks.
Trial: NCT05579184
Drug: [177Lu]Ludotadipep
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive 100 mCi of \[177Lu\]Ludotadipep every 8 \[±1\] weeks (up to 6 times)~* Test article code/name: \[177Lu\]Ludotadipep~* Administration route: intravenous injection~* Total dose strength: 4 to 6 x 3.7 GBq~* Dosage form: solution for injection
Trial: NCT00012688
Drug: Doxycycline HCI 10mg po for 2 weeks
RxNorm normalized name: Doxycycline for Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06482684
Drug: KTE-X19
FDA approved: no
EMA approved: no
PMDA approved: no
Description: See description of treatment arms
Trial: NCT04982211
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo capsules, dosed per participant weight
Trial: NCT05468242
Drug: Neoadjuvant chemo-immunotherapy
RxNorm normalized name: Chem-Star Recover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The neoadjuvant chemo-immunotherapy before radiotherapy comprised of chemotherapy plus Tislelizumab \[200 mg, once every 3 weeks (Q3W)\].
Trial: NCT04923113
Drug: Rabeprazole，Minocycline，Amoxicillin and Colloidal bismuth pectin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Helicobacter pylori positive patients will be treated with rabeprazole10mg,minocycline 100mg,amoxicillin1000mg,and colloidal bismuth pectin 200mg,all twice daily for 10 days
Trial: NCT04984057
Drug: PS is stopped when the pressure is equal between bPDA and aPDA.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PS is given and stopped when the pressure is equal between bPDA and aPDA. the pressure is measured using ultrasound
Trial: NCT06649136
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: comparison between oral and subcutaneous methotrexate dosis of 25mg
Trial: NCT04988971
Drug: a compound glutamine capsule simulated placebo
RxNorm normalized name: glutamine Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a compound glutamine capsule simulated placebo was taken orally from the first day of chemotherapy, orally 3 times a day after meals, 3 tablets each time, the course of treatment is 3 weeks.
Trial: NCT06172036
Drug: Adebellizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efficacy and safety of irinotecan liposome combined with oxaliplatin, 5-fluorouracil (5-FU) / leucovorin calcium (LV) with or without adbellizumab for resectable pancreatic cancer
Trial: NCT02129751
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo arm
Trial: NCT06666010
Drug: PEX010-Assisted Therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The investigational medicinal product PEX010, containing 25 mg psilocybin, is a capsule for oral administration that contains the drug substance PYEX.
Trial: NCT06666010
Drug: PEX010(01)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The investigational medicinal product PEX010(01), containing 1 mg psilocybin, is a capsule for oral administration that contains the drug substance PYEX.
Trial: NCT05036577
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: high-dose Methotrexate 3.5 g/m2 or 5g/m2 intravenous infusion (3h) d2, every 21 days for 6-8 cycels during combination induction treatment.
Trial: NCT02414178
Drug: F 18 T807
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
Trial: NCT04679012
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. The drug will be given by IV route.
Trial: NCT06666959
Drug: Anesthesia Agent
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous anesthetic and inhalation anesthetic
Trial: NCT06231680
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platinum-based chemotherapy:~1. Esophageal squamous cell carcinoma: cisplatin/carboplatin/nedaplatin/lobaplatin+ paclitaxel/albumin-bound paclitaxel/fluorouracil on Day 1 of each 21-day cycle for 4-6 cycles;~2. Non-small cell lung cancer (non-squamous cell carcinoma): pemetrexed plus carboplatin/cisplatin on Day 1 of each 21-day cycle for 4-6 cycles，pemetrexed every three weeks (Q3W) maintenance for the remainder of the study or until documented PD;~3. Non-small cell lung cancer (squamous cell carcinoma) : paclitaxel/albumin-bound paclitaxel + carboplatin/cisplatin on Day 1 of each 21-day cycle for 4-6 cycles.
Trial: NCT01511822
Drug: Drospirenone Ethinyl estradiol
RxNorm normalized name: drospirenone / ethinyl estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drospirenone 3mg/die Ethinyl estradiol 30 mg/die (21 days/month for 6 months)
Trial: NCT01511822
Drug: Drospirenone Ethinyl estradiol Myo-inositol
RxNorm normalized name: myo-inositol
DrugBank: Inositol (DB13178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drospirenone 3mg/die Ethinyl estradiol 30 mg/die (21 days/months for 6 months) + Myo-inositol 6g /die for 6 months
Trial: NCT01511822
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05367284
Drug: Testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testogel 16.2 miligrams/ gram (mg/g) gel
Trial: NCT04798989
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Oral Tablet
Trial: NCT06621836
Drug: ICPB H
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICPB technique The patient's head will be rested on a pillow and turned to the opposite side. A linear probe with higher frequencies will be placed transversely over the midpoint of the SCM muscle. The carotid artery will be identified and traced upwards to its bifurcation. the probe will be then moved laterally to identify the tapering posterolateral end of the SCM muscle. Via an in-plane technique, a 22-gauge, 50 mm needle will be advanced underneath the investing fascia of SCM muscle and above the interscalene groove until feeling the pop on piercing the investing fascia. The patient will be then randomly allocated into two groups (H \& L) using computer-generated random numbers that will be concealed in opaque envelopes. Group H will receive 10 ml 0.25 % bupivacaine he technique will be repeated on the opposite side
Trial: NCT06429345
Drug: Coenzyme Q10 100 Milligrams Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be randomly divided into two groups using a computer generated random number chart Coenzyme Q10 group will receive 400 milligrams coenzyme Q10 preoperative and 400 milligrams coenzyme Q10 for 3 days post operative in addition to the standard preventive measures.
Trial: NCT06429345
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo group will receive only the standard preventive measures (as proper hydration pre and post operative)without the coenzyme Q10.
Trial: NCT04910685
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral tablet
Trial: NCT05335447
Drug: GLPG3667 capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On Day 1, participants will receive a single oral dose of GLPG3667
Trial: NCT05335447
Drug: [14C]-GLPG3667 solution for infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On Day 1, participants will receive a single microtracer microdose of \[14C\]-GLPG3667 as an intravenous infusion
Trial: NCT05335447
Drug: [14C]-GLPG3667 capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On Day 1, participants will receive a single oral dose of \[14C\]-GLPG3667
Trial: NCT05051696
Drug: H101
RxNorm normalized name: Avicel PH101 (Microcrystalline Cellulose NF) for Compounding
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-tumor injected oncolytic viruses H101 within 5 consecutive days,3 weeks for a cycle (1-4cycles)
Trial: NCT05202327
Drug: PDC-1421 Capsule
RxNorm normalized name: chlorpheniramine maleate / dihydrocodeine bitartrate / phenylephrine hydrochloride Oral Solution [Despec-PDC]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PDC-1421 Capsule is a botanical investigational new drug containing the extract of Radix Polygalae (Polygala tenuifolia Willd.) as the active ingredient.
Trial: NCT05970822
Drug: BC3402
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalating of BC3402 will be administered IV(intravenous)
Trial: NCT05502146
Drug: Noradrenaline Bitartrate
RxNorm normalized name: Noradrenaline bitartrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An intravenous bolus of norepinephrine 6 mcg will be administered for management of maternal hypotension.